Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desiglucagon in infants with congenital hyperinsulinism
MOH_2019-05-13_007133Phase 3Completed
- Sponsor
- Zealand Pharma
- Start
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in congenital hyperinsulinism (HI) comparing Desiglucagon with Placebo (2 arms). Started Feb 2019; status: completed.
02
Drugs
dasiglucagon
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on MOH_2019-05-13_007133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-13_007133.